Efficacity and Safety of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding (EXARHOSE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03023189|
Recruitment Status : Unknown
Verified April 2018 by Assistance Publique - Hôpitaux de Paris.
Recruitment status was: Recruiting
First Posted : January 18, 2017
Last Update Posted : April 11, 2018
Upper digestive bleeding. Upper gastrointestinal haemorrhage is a common cause of decompensated cirrhosis and is associated with a high mortality rate among cirrhotic patients. Its leading cause is the rupture of gastro-esophageal varices due to portal hypertension. In cirrhotic patients, the management of acute gastrointestinal haemorrhage is challenging as they often present with coagulation (or haemostasis abnormalities) abnormalities such as hyperfibrinolysis, especially when the cirrhosis is decompensated. Beyond life support measures, therapeutic modalities of upper gastrointestinal bleeding rely on both endoscopic and pharmacological interventions. Tranexamic acid (TA) is an antifibrinolytic that may help control the bleeding in this setting, as it showed an unquestionable benefit in other indications. TA has previously been studied in both upper gastrointestinal haemorrhage from any causes and in liver transplantation of cirrhotic patients. However, there is a lack of data to conclude on its effectiveness (or efficiency) in the early treatment of acute bleeding in cirrhotic patients.
Investigators hypothesize that, when given early, TA would be beneficial for cirrhotic patients presenting with acute upper gastrointestinal haemorrhage , by controlling the haemorrhage, avoiding rebleeding episodes and reducing mortality within 5 days after its administration. Moreover, TA could prevent early cirrhosis complications (such as hepatic encephalopathy, sepsis and ascites liquid infection, hepatorenal syndrome), could reduce indications to transjugular portosystemic shunt (TIPS), shorten the length of stay in intensive care unit and the length of hospitalization, and decrease late relapses and one-year mortality.
|Condition or disease||Intervention/treatment||Phase|
|Upper Digestive Bleeding Cirrhosis||Drug: Tranexamic acid Drug: Placebo||Phase 4|
Acute Upper gastrointestinal haemorrhage (UGIH) is frequent, with an estimated annual incidence of 150/100 000 in France. Its second etiology is the rupture of portal hypertension-related gastro-esophageal varices, accounting for 20 % of the patients and responsible for more than 50 % of the hospitalizations in intensive care unit (ICU) for UGIH.
In cirrhotic patients, variceal bleeding is the main cause of UGIH (over 70 %) and death (30 %), which occurs in the most severe patients (Child-Pugh score B or C and/or high MELD score, and high levels of portal hypertension).
Acute UGIH is directly responsible for 50 % of the deaths, either because it remains uncontrolled during the acute phase (within 5 days), or because of early relapses (within 6 weeks). Every episode of acute UGIH worsens the middle and long-term vital prognosis: about 60 % of the patients present with UGIH recurrence within one year and the survival rate is only 30 % 3 years after the first episode.
Moreover, acute UGIH is a triggering factor for several severe cirrhosis-specific complications (such as hepatic encephalopathy, sepsis and ascites liquid infection, hepatorenal syndrome), which themselves lead to high mortality rates. Despite the improvement of preventive, diagnostic and therapeutic strategies, UGIH remains stable in France.
The haemostasis of cirrhotic patients is often abnormal at baseline : thrombopenia, decrease of factors II, V, VII, IX, X and XI, decrease of fibrinolytic proteins, increase of factor VIII and spontaneous fibrinolysis. When compensated, the cirrhotic's haemostasis remains globally preserved, due to the balance of pro and anticoagulant alterations.
Every cause of cirrhosis decompensation, such as acute PHT-UGIH, can increase hemostatic disorders, leading to hyperfibrinolysis. This could slow down or inhibit the clotting, thus disrupting pharmacological control of acute UGIH.
TA could be efficient in acute UGIH of cirrhotic patients. It is a simple antifibrinolytic which showed clinical benefits on haemorrhage and/or mortality in several other indications (surgical, obstetrical and traumatic). It is now widely used according to recommendations.
Early administration of TA seems to be beneficial in UGIH haemorrhage. Despite theoretical efficiency, 4 recent Cochrane meta-analysis concluded to the lack of significant data (poor overall trials quality). The benefit of the use of TA in acute UGIH (and acute PHT-UGIH) remains uncertain.
At this day, TA has still not been studied in acute UGIH of cirrhotic patients, although it showed benefits on blood transfusion's requirements and on haemorrhagic complications during liver transplantation (for which cirrhosis most frequent cause).
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||500 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Efficacy and Safety of Early Administration of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding: a Multicenter, Randomized, Double Blind, Placebo-controlled Trial (Modified by amendment1)|
|Actual Study Start Date :||April 3, 2017|
|Estimated Primary Completion Date :||April 2019|
|Estimated Study Completion Date :||April 2020|
Active Comparator: Tranexamic acid
At randomisation : loading dose of 1g of intravenous tranexamic acid for 10 min, immediately followed by an intravenous infusion of 3g of TA over 24h
Drug: Tranexamic acid
At randomisation : loading dose of 1g of intravenous tranexamic acid for 10 min, immediately followed by an intravenous infusion of 3g of TA over 24h.
Total dose : 4 g of TA
Placebo Comparator: Placebo
At randomisation : loading dose of 10 mL of intravenous isotonic saline for 10 min, immediately followed by an intravenous infusion of 30 mL of isotonic saline over 24h
At randomisation : loading dose of 10 mL of intravenous isotonic saline for 10 min, immediately followed by an intravenous infusion of 30 mL of isotonic saline over 24h Total dose : 40 mL of Placebo
- The main outcome is a composite criterion and includes: control on acute bleeding, absence of re-bleeding episodes at day 5 and absence of death at day 5 (modified by amendment 1) [ Time Frame: 5 days after randomisation ]
Specifically, the composite criterion is defined by all the following criteria:
- Immediate control of the hemorrhage after initial patient management using splanchnic vasoconstrictors and/or proton pump inhibitors, potentially including volume expander, transfusion and/or prescription of vasopressor amines :
- Achievement of the transfusion target (Hb ≥ 7 g/dL) 24 hours after initial patient management and then until day 5
- Absence of initiation or increase in vasopressor amines, until day 5
- Absence of recourse to the transfusion of 2 or more red cells packs within 24h to maintain the transfusion target (Hb ≥ 7 g/dL)
- Absence of persistence or evolution towards haemorrhagic shock (systolic blood pressure < 100 mmHg and/or mean arterial pressure < 60 mmHg and/or heart rate > 100 bpm)
- Absence of re-bleeding episodes at day 5, assessed by the medical team on the bases of clinical, biological or endoscopic elements
- Absence of death at day 5
- Control of the bleeding [ Time Frame: Within 5 days after randomisation ]
At least 1 criterion present :
- Persistence of the bleeding (regardless of the volume), 2 hours after initiation of medical or endoscopic treatment
- And/Or blood transfusion needed within 24 hours after treatment initiation (≥ 2 red cells units)
- And/Or hemorrhagic shock installation (systolic blood pressure < 100 mmHg and/or mean arterial pressure < 60 mmHg and/or heart rate > 100 bpm)
- Re-bleeding episodes [ Time Frame: At day 6, day 28, day 42, 3 months, 6 months and 1 year after randomisation ]
- Death [ Time Frame: At day 6, day 28, day 42, 3 months, 6 months and 1 year after randomisation ]
- Fluid infusion volume (in mL) [ Time Frame: At day 6, day 28 and day 42 after randomisation ]
- Blood transfusion volume (in mL) [ Time Frame: At day 6, day 28 and day 42 after randomisation ]
- Blood transfusion quantity (number of units) [ Time Frame: At day 6, day 28 and day 42 after randomisation ]
- Nature of blood transfusion: - Red cells units - Platelets units - Fresh frozen plasma - Fibrinogen - Other [ Time Frame: At day 6, day 28 and day 42, after randomisation ]
- TIPS procedure (in Child-Pugh B patients) [ Time Frame: At day 6, day 28, day 42 after randomisation ]
- Visceral and systemic complications [ Time Frame: At day 6, day 28 and day 42, after randomisation (or until discharge) ]
Complications, defined as:
- Acute organ failure (using CLIF-C ACLF and CLIF-SOFA scores)
- Hepatic encephalopathy
- Hepatic failure
- Hepatorenal syndrome
- Renal failure (using grades 2 and 3 of the KDIGO classification)
- Ascites liquid infection
- Need for organ substitution - Renal replacement therapy (dialysis) - Liver replacement therapy - Mechanical ventilation [ Time Frame: At day 6, day 28 and day 42, after randomisation (or until discharge) ]
- Liver transplantation [ Time Frame: At day 6, day 28, day 42, 3 months, 6 months and 1 year after randomisation ]
- Length of stay in ICU (in days) [ Time Frame: At day 6, day 28, day 42, 3 months, 6 months and 1 year after randomisation ]
- Duration of hospitalization (in days) [ Time Frame: At day 6, day 28, day 42, 3 months, 6 months and 1 year after randomisation ]
- Number of participants with treatment-related adverse events as assessed by the ANSM notice of Exacyl® [ Time Frame: up to 5 days ]
Adverse events as assessed by the ANSM notice of Exacyl® are :
- Thrombotic events
- Acute renal failure (KDIGO grades 2 and 3)
- Or any other adverse event suspected to be treatment-related
Adverse effects will be systematically searched for and collected in the electronic Case Report Form (eCRF) during the acute phase (within 5 days after randomization), as assessed by the AP-HP notification form. When present, investigators will have to send a notification to the promoter (by fax). Patients with severe adverse effects (leading to death, life-threatening condition, hospitalization and pursuit of hospitalization, incapacity or handicap, congenital malformation) will be followed until disappearance of these. Every document related to the patient during the protocol should be transmitted to the promoter. Investigators are supposed to answer every inquiry of the promoter.
- Delay between the beginning of the haemorrhage and the initiation of the AT treatment [ Time Frame: At day 1 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03023189
|Contact: Matthieu HEIDET, MDfirstname.lastname@example.org|
|Contact: Roland AMATHIEU, MDemail@example.com|
|Jean Verdier Hospital||Recruiting|
|Bondy, France, 93140|
|Contact: Roland Amathieu, MD firstname.lastname@example.org|
|Henri Mondor Hospital||Recruiting|
|Creteil, France, 94010|
|Contact: Matthieu HEIDET, MD email@example.com|
|Marc Jacquet Hospital||Recruiting|
|Melun, France, 77000|
|Contact: Line JACOB, MD firstname.lastname@example.org|
|Principal Investigator:||Matthieu HEIDET||Assistance Publique - Hôpitaux de Paris|